These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19648797)

  • 1. Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease.
    Rao K; Rao A; Karlsson H; Jagani M; Veys P; Amrolia PJ
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):456-61. PubMed ID: 19648797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept.
    Wolff D; Roessler V; Steiner B; Wilhelm S; Weirich V; Brenmoehl J; Leithaeuser M; Hofmeister N; Junghanss C; Casper J; Hartung G; Holler E; Freund M
    Bone Marrow Transplant; 2005 May; 35(10):1003-10. PubMed ID: 15806135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclizumab for children with corticosteroid refractory graft-versus-host disease.
    Teachey DT; Bickert B; Bunin N
    Bone Marrow Transplant; 2006 Jan; 37(1):95-9. PubMed ID: 16247417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease.
    Perales MA; Ishill N; Lomazow WA; Weinstock DM; Papadopoulos EB; Dastigir H; Chiu M; Boulad F; Castro-Malaspina HR; Heller G; Jakubowski AA; O'Reilly RJ; Small TN; Young JW; Kernan NA
    Bone Marrow Transplant; 2007 Sep; 40(5):481-6. PubMed ID: 17618322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
    Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
    Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
    Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience.
    Miano M; Cuzzubbo D; Terranova P; Giardino S; Lanino E; Morreale G; Castagnola E; Dini G; Faraci M
    Bone Marrow Transplant; 2009 Mar; 43(5):423-7. PubMed ID: 18850021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
    Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
    Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation.
    Yang J; Cheuk DK; Ha SY; Chiang AK; Lee TL; Ho MH; Chan GC
    Pediatr Transplant; 2012 Nov; 16(7):771-8. PubMed ID: 22905718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
    Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
    Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis.
    Srinivasan R; Chakrabarti S; Walsh T; Igarashi T; Takahashi Y; Kleiner D; Donohue T; Shalabi R; Carvallo C; Barrett AJ; Geller N; Childs R
    Br J Haematol; 2004 Mar; 124(6):777-86. PubMed ID: 15009066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclizumab therapy for children with corticosteroid-resistant acute graft-vs.-host disease.
    Schechter T; Afzal S; Finkelstein Y; Koren G; Doyle J; Dupuis LL
    Pediatr Transplant; 2009 May; 13(3):332-7. PubMed ID: 18482218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease.
    Gómez-Almaguer D; Ruiz-Argüelles GJ; del Carmen Tarín-Arzaga L; González-Llano O; Gutiérrez-Aguirre H; Cantú-Rodríguez O; Jaime-Pérez J; Carrasco-Yalán A; Giralt S
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):10-5. PubMed ID: 18158956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
    Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
    Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease.
    Bordigoni P; Dimicoli S; Clement L; Baumann C; Salmon A; Witz F; Feugier P
    Br J Haematol; 2006 Nov; 135(3):382-5. PubMed ID: 16984386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
    Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
    Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab for GVHD therapy in children.
    Sleight BS; Chan KW; Braun TM; Serrano A; Gilman AL
    Bone Marrow Transplant; 2007 Sep; 40(5):473-80. PubMed ID: 17618323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.